We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

146 hedge funds and large institutions have $869M invested in Enanta Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,897% more call options, than puts

Call options by funds: $10.6M | Put options by funds: $176K

16% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 49

2.64% less ownership

Funds ownership: 95.08% → 92.44% (-2.6%)

8% less funds holding

Funds holding: 159 → 146 (-13)

15% less capital invested

Capital invested by funds: $1.02B → $869M (-$153M)

55% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 22

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
146
Holders Change
-13
Holders Change %
-8.18%
% of All Funds
2.35%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
10
Increased
57
Reduced
49
Closed
22
Calls
$10.6M
Puts
$176K
Net Calls
+$10.4M
Net Calls Change
-$94K

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$12.2M
2
State Street
State Street
Massachusetts
+$6.14M
3
BlackRock
BlackRock
New York
+$6.03M
4
CC
Commodore Capital
New York
+$5.47M
5
CCM
Camber Capital Management
Massachusetts
+$5.01M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$46.5M
2
FFM
Fairmount Funds Management
Pennsylvania
-$24.3M
3
Invesco
Invesco
Georgia
-$11.4M
4
Northern Trust
Northern Trust
Illinois
-$3.71M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$5.5M -$150K -3,295 -3%
Citadel Advisors
27
Citadel Advisors
Florida
$5.12M +$3.47M +76,104 +224%
CCM
28
Camber Capital Management
Massachusetts
$5.12M +$5.01M +110,000 New
Invesco
29
Invesco
Georgia
$4.96M -$11.4M -249,578 -70%
CS
30
Candriam SCA
Luxembourg
$4.68M – – –
EAM
31
Erste Asset Management
Austria
$4.4M +$912K +20,000 +27%
Rafferty Asset Management
32
Rafferty Asset Management
New York
$3.88M +$898K +19,692 +31%
PAMS
33
Pictet Asset Management (Switzerland)
Switzerland
$3.39M +$859K +18,840 +35%
N
34
Nuveen
North Carolina
$2.86M -$415K -9,095 -13%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$2.79M +$2.73K +60 +0.1%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$2.63M +$451K +9,900 +21%
Legal & General Group
37
Legal & General Group
United Kingdom
$2.62M +$64K +1,404 +3%
Millennium Management
38
Millennium Management
New York
$2.61M +$843K +18,499 +49%
Bank of America
39
Bank of America
North Carolina
$2.57M +$518K +11,370 +26%
HIM
40
Hillsdale Investment Management
Ontario, Canada
$2.48M – – –
Assenagon Asset Management
41
Assenagon Asset Management
Luxembourg
$2.44M +$1.34M +29,353 +127%
Barclays
42
Barclays
United Kingdom
$2.37M +$252K +5,531 +12%
Citigroup
43
Citigroup
New York
$2.26M -$986K -21,634 -31%
Swiss National Bank
44
Swiss National Bank
Switzerland
$2.21M +$36.5K +800 +2%
New York State Teachers Retirement System (NYSTRS)
45
New York State Teachers Retirement System (NYSTRS)
New York
$1.88M – – –
UBS Group
46
UBS Group
Switzerland
$1.77M +$1.63M +35,838 +1,645%
PGA
47
Portland Global Advisors
Maine
$1.68M – – –
Public Sector Pension Investment Board (PSP Investments)
48
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.66M – – –
CSS
49
Cubist Systematic Strategies
Connecticut
$1.62M -$251K -5,499 -14%
Two Sigma Investments
50
Two Sigma Investments
New York
$1.49M +$817K +17,922 +126%
1
2
3 4 5

ENTA Hedge Fund Activity: Q4 2022 in Review

146 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2022, worth a combined $869M — down 15% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ENTA and 10 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 57 added.

The largest buyer was UBS AM, adding an estimated $12.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $46.5M sold.

  • 146 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2022, down from 159 in Q3 2022.
  • Funds reported $869M of Enanta Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
  • 10 funds opened new Enanta Pharmaceuticals positions in Q4 2022 and 22 closed out, a net change of -12 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2022 was UBS AM, an estimated $12.2M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $46.5M sold.

Based on aggregated 13F filings for Q4 2022.